Regeneron (REGN) Reports Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DFTX
4. IBM
5. META
6. MU
7. DPZ
8. ACN
9. ZENA
10. CNC

Go back to Regeneron (REGN) Reports Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

February 27, 2021 6:25 PM EST

TARRYTOWN, N.Y., Feb. 27, 2021 /PRNewswire/ --

Single administration of novel antibody cocktail controlled patients' allergic response to cat allergen, preventing early asthma reactions for the duration of the 3-month trial

Patients experienced significant improvements in lung function and cat allergen tolerance from the first assessment at week 1

Results presented at the virtual 2021 AAAAI Annual Meeting

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced detailed results from a Phase 2 proof-of-concept trial evaluating the investigational antibody cocktail REGN1908-1909 in cat-allergic patients with mild asthma.... More